- Home
- IONS vs TEO Comparison
IONS vs TEO Comparison
Compare IONS & TEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- TEO
- Stock Information
- Founded
- IONS 1989
- TEO 1979
- Country
- IONS United States
- TEO Argentina
- Employees
- IONS N/A
- TEO N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- TEO Telecommunications Equipment
- Sector
- IONS Health Care
- TEO Telecommunications
- Exchange
- IONS Nasdaq
- TEO Nasdaq
- Market Cap
- IONS 6.0B
- TEO 5.9B
- IPO Year
- IONS 1991
- TEO N/A
- Fundamental
- Price
- IONS $31.43
- TEO $12.00
- Analyst Decision
- IONS Buy
- TEO Sell
- Analyst Count
- IONS 18
- TEO 1
- Target Price
- IONS $62.00
- TEO $6.10
- AVG Volume (30 Days)
- IONS 1.5M
- TEO 282.1K
- Earning Date
- IONS 02-19-2025
- TEO 11-07-2024
- Dividend Yield
- IONS N/A
- TEO N/A
- EPS Growth
- IONS N/A
- TEO N/A
- EPS
- IONS N/A
- TEO 0.21
- Revenue
- IONS $803,067,000.00
- TEO $1,780,106,477.00
- Revenue This Year
- IONS N/A
- TEO N/A
- Revenue Next Year
- IONS $10.85
- TEO N/A
- P/E Ratio
- IONS N/A
- TEO $13.49
- Revenue Growth
- IONS 30.57
- TEO N/A
- 52 Week Low
- IONS $31.41
- TEO $5.52
- 52 Week High
- IONS $52.49
- TEO $15.54
- Technical
- Relative Strength Index (RSI)
- IONS 33.19
- TEO 41.42
- Support Level
- IONS $32.61
- TEO $12.45
- Resistance Level
- IONS $35.37
- TEO $13.59
- Average True Range (ATR)
- IONS 1.28
- TEO 1.04
- MACD
- IONS -0.30
- TEO -0.17
- Stochastic Oscillator
- IONS 0.36
- TEO 2.48
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
About TEO Telecom Argentina SA
Telecom Argentina SA offers its customers quadruple play services, combining mobile telephony services, cable television services, Internet services and fixed telephony services. It also provides other telephone-related services such as international long-distance and wholesale services, data transmission and IT solutions outsourcing and install, operate and develop cable television and data transmission services. The company provides services in Argentina (mobile, cable television, Internet and fixed and data services), Paraguay (mobile, Internet and satellite TV services), Uruguay (cable television services) and the United States (fixed wholesale services).